Title: Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Journal: Chemical research in toxicology 20170515
Title: Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Journal: PLoS computational biology 20111201
Title: Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Journal: Bioorganic & medicinal chemistry 20101215
Title: A predictive ligand-based Bayesian model for human drug-induced liver injury.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20101201
Title: Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal: Journal of medicinal chemistry 20050630
Title: Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal: Journal of medicinal chemistry 20030605
Title: Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.
Journal: Bioorganic & medicinal chemistry letters 20020805
Title: Pharmacology of AT1-receptor blockers.
Journal: Blood pressure. Supplement 20010101
Title: Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
Journal: The Journal of pharmacology and experimental therapeutics 20001101
Title: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal: Journal of medicinal chemistry 19960202
Title: Maillard MP, et al. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
Title: Elokdah HM, et al. Novel human metabolites of the angiotensin-II antagonist Tasosartan and their pharmacological effects. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71.
